YUCAIPA, Calif., Jan. 5, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News ), a leading global Medical Device Manufacturer for the Oxyview Nasal Cannula, focused on the $4B Respiratory market for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that they have signed a Supply Agreement with Amsino International Inc. on December 1, 2009.
The Pomona-California based Amsino was established in 1993 and is a leading medical device developer and manufacturer dedicated to advancing healthcare worldwide by developing, manufacturing, and marketing medical products that help improve the safety and effectiveness of patient care. Amsino's product and service portfolio includes infusion products and access devices, blood collection and transfusion devices, anesthesia and surgical products, urological products, enteral feeding and irrigation products, respiratory therapy products, patient care products, and a full-service contract manufacturing business. Amsino products are distributed in the United States and more than 30 other countries worldwide.
E-Mail this Article to a Friend Print this Article
Ingen and Amsino will manufacture the Oxyview and Oxyview Nasal Cannula at a reduced cost compared to current manufacturing costs. The Supply Agreement is effective for a 3-year term and is renewable.
Ingen is ready for ISO 13485 Certification and is now waiting in line for an audit date in January-2010. The company expects to be certified and the CE Mark and distribution of product will follow. The company expects GSA approval and will make an announcement in January. Both ISO certification and GSA will expand product distribution to U.S. Government branches, inclusive of the Department of Defense and the VA Hospital network, as well as export to China, Japan, Canada, Australia and Europe.
"We look forward to working with Richard Lee, CEO of Amsino, and his professional team. This agreement allows Ingen to reduce manufacturing costs by 40%, and increase efficiency and quality of our respiratory product line. Amsino International was introduced to us through Pacific Pearl Group, our Investment Banking consultants, who have evaluated Amsino as a good fit for manufacturing and distribution of the Ingen product line. With ISO certification near completion and GSA close to approval, the relationship between Amsino and Ingen is expected to be a prosperous one," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
YUCAIPA, Calif., Jan. 5, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News ), a leading global Medical Device Manufacturer for the Oxyview Nasal Cannula, focused on the $4B Respiratory market for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that they have signed a Supply Agreement with Amsino International Inc. on December 1, 2009.
The Pomona-California based Amsino was established in 1993 and is a leading medical device developer and manufacturer dedicated to advancing healthcare worldwide by developing, manufacturing, and marketing medical products that help improve the safety and effectiveness of patient care. Amsino's product and service portfolio includes infusion products and access devices, blood collection and transfusion devices, anesthesia and surgical products, urological products, enteral feeding and irrigation products, respiratory therapy products, patient care products, and a full-service contract manufacturing business. Amsino products are distributed in the United States and more than 30 other countries worldwide.
Ingen and Amsino will manufacture the Oxyview and Oxyview Nasal Cannula at a reduced cost compared to current manufacturing costs. The Supply Agreement is effective for a 3-year term and is renewable.
Ingen is ready for ISO 13485 Certification and is now waiting in line for an audit date in January-2010. The company expects to be certified and the CE Mark and distribution of product will follow. The company expects GSA approval and will make an announcement in January. Both ISO certification and GSA will expand product distribution to U.S. Government branches, inclusive of the Department of Defense and the VA Hospital network, as well as export to China, Japan, Canada, Australia and Europe.
"We look forward to working with Richard Lee, CEO of Amsino, and his professional team. This agreement allows Ingen to reduce manufacturing costs by 40%, and increase efficiency and quality of our respiratory product line. Amsino International was introduced to us through Pacific Pearl Group, our Investment Banking consultants, who have evaluated Amsino as a good fit for manufacturing and distribution of the Ingen product line. With ISO certification near completion and GSA close to approval, the relationship between Amsino and Ingen is expected to be a prosperous one," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
| INGEN TECHNOLOGIES, INC. Stock Symbol :: IGNT |
|
 | INGEN TECHNOLOGIES, INC. (IGNT) Ingen Technologies, Inc. is an established medical device manufacturer with an emerging new medical product line for the respiratory market | |||||||||||
Ingen Technologies, Inc. 35193 Avenue "A" Suite-C Yucaipa, CA 92399 Phone: (800) 259-9622 Fax: 800-777-1186 http://www.ingen-tech.com |
· American Homepatient, Inc. provides home healthcare services and products consisting primarily of respiratory therapy services, home infusion therapy services, and the rental and sale of home medical equipment and home health care supplies. The Company’s services and products are paid for primarily by Medicare, Medicaid, and other third-party payors. OTCBB:AHOM Recent Price: $.23 · Lincare Holdings Inc. (Lincare) is a provider of oxygen and other respiratory therapy services to patients in the home. Lincare’s customers suffer from chronic obstructive pulmonary disease (COPD), such as emphysema, chronic bronchitis or asthma, and require supplemental oxygen or other respiratory therapy services in order to alleviate the symptoms and discomfort of respiratory dysfunction. Lincare primarily provides oxygen and other respiratory therapy services to patients in the home. NASDAQ:LNCR Recent Price: $31.41 |
| Current Projects |
 | Ingen Brings Aboard Leading OEM Partner for Australia Ingen Technologies, Inc., recently announced that Medical Industries Australia has signed an OEM contract with Ingen. Approximately 1,000 COPD patients, each day, occupy a public hospital bed in Australia (at a cost of $580 per day). In many cases it's due to an exacerbation requiring a respiratory investigative review with new titration and oxygen therapy needs established. Approximately 30,000 patients use Oxygen concentrators on a daily basis. Medical Industries Australia is a leading provider of sterile and non-sterile medical products, training and maintenance services for more than 20 years. | Ingen Cuts Manufacturing Costs and Increases Its Margins Ingen Technologies, Inc. recently received a proposal from a leading manufacturer to help reduce production costs and material costs by 50% for the manufacture of the Oxyview and the Oxyview Nasal Cannula. Now that they are selling their respiratory products, and sales have escalated, they must reduce their cost of goods sold in order to increase their profit margins and decrease the costs to their dealers and buyers. This change will give the company a stronger foot-hold in the market. The company has a proprietary product and there is nothing in the marketplace that can compete with their device. |
| Company Overview |
Ingen, Inc. (OTC.PK: IGNT) Ingen Technologies brings over 20 years of experience and dedication to the design and support of medical devices, Ingen has helped many medical professionals meet clinical and economic objectives. Ingen has developed medical products that provide a valuable benefit to the patient and cost savings to the insurance companies, Medicare and essentially the tax payer. The medical products provide a focus for the ever-increasing elderly population. These products are superior to any of our competition and they allow for effective medical product availability to seniors. Ingen’s Mission: Their Commitment to CustomersIngen is committed to meeting the needs of their customers through ongoing product innovation and support. Ingen distributes its products through a national distributor network domestically and in Canada, Asia and European Communities. Ingen’s commitment to customers continues beyond the sale of their product. The BeginningIngen, originally a privately owned company founded for the purpose of providing medical solutions for our growing healthcare market, is now a publicly traded company and growing medical device manufacturer. In 1999, Ingen founders invested several millions of dollars in the research and development of state-of-the-art respiratory monitoring devices, with a focus on helping patients and preventing unnecessary costs to the healthcare system. With multiple patents, FDA classification and certifications, Ingen is the largest manufacturer of gravity-independent in-line oxygen flow meters, meeting the demand of the growing patient population and service providers. Their products are manufactured in the USA. Their CapabilitiesThe company is proud of their capabilities in gas flow-meter technology and wireless digital data transfer of gas flow rate processing. Ingen is the first company to patent and develop transducers that detect oxygen flow rate and provide data transfer. This has revolutionized the oxygen therapy market providing user friendly solutions in monitoring oxygen levels and oxygen delivery systems. Ingen Technologies, Inc. introduces Oxyview®, the World's First Patient In-Line Oxygen Flow-Meter. Another innovative respiratory product manufactured in the USA by Ingen Technologies; providing more confidence and assurance to patients using oxygen. Oxyview® is reusable, requires no batteries, works all the time in any position with all liquid or gas O2 systems, and easily installs anywhere below the cannula nearest the patient where oxygen flow matters the most. Oxygen suppliers and patients will appreciate that Oxyview® prevents many unnecessary service calls. Oxygen is an element, a gas, and a drug that can help people who have certain lung diseases. The cells in the body get their energy from the interaction of oxygen with food. The energy produced is used to do everything from breathing, to carrying out bodily functions, to going to the grocery store. Some lung diseases, such as emphysema and sarcoidosis, reduce lung function to the extent that supplemental oxygen is needed to continue normal bodily function. For many people with end stage lung disease, supplemental oxygen allows their bodies to get the oxygen that they need and may also help them be more active. To say that we need oxygen to exist is as obvious as saying we need water. But as we all know, water can also be a destructive force. The key, of course, is having the right amount in the right place at the right time. That is just as important for oxygen, especially for those who require supplementary oxygen. An essential component to this remedy is a flow meter to ensure that the right amount of oxygen is being delivered, and just as important that it is being delivered at all. Regardless of the use of an oxymeter to measure blood gas, Oxyview®provides vital information related to functionality of the cannula and all of the oxygen equipment. If something is wrong with the cannula or equipment, the Oxyview® will show you immediately. This is usually achieved by a pneumatic flow meter, but most that are currently on the market are expensive, attach at the tank, and are gravity-operated, which means that they only work in the vertical position with or without the cannula attached at the delivery source. In contrast, Oxyview® attaches to the cannula close to the patient— where oxygen matters the most. Oxyview® is 97 percent accurate and works hands-free in any position, whereas the conventional flow meter is less than 80 percent accurate and does not attach to the cannula. Gravity-operated devices are also inconvenient for the patient since they must keep the tanks within sight to check the gauges for flow rate. If the tank is tilted even slightly, the gravity-operated flow meter becomes even more inaccurate and may cease functioning because friction is too great. One alternative is a digital flow meter, but these may be prohibitively expensive. That’s why the Oxyview® flow meter (Ingen Technologies, Inc., Yucaipa, CA) is a significant advance in the technology. When first launched in November 2007, it represented a new generation of pneumatic real-time safety devices. It has some notable features: accurate to within + 3% and versatile enough to work with all respiratory equipment—CP AP, concentrators, liquid and gas cylinders, on-demand conservers and more. It is not gravity-dependent and so can be placed at any point in the tubing, even by the patients themselves. Having the device close by for easy viewing allows the patient assurance and confidence, knowing that there is a flow of oxygen at the correct level. They are also able to quickly see if the regulator or concentrator is not working properly. Listed are some of the recent hightlights from the 2009 IGNT Annual Meeting An increase in sales is forecast with a first quarter-2009 reporting of $105,717 in Oxyview revenues. Medica and Medtrade convention - Emergo group will debut the new Oxyview Nasal Cannula at Medtrade in Atlanta, GA in October- 2009 and Medica in Germany in November-2009. This will garner product exposure and increased awareness. Chest Physicians Annual Meeting - The Medco Forum publication debuts a front cover ad and editorial of the new Oxyview Nasal Cannula to be distributed to more than 13,000 chest physicians at the October-2009 annual meeting. Increase in sales for first quarter - a) Mr. Sand said Ingen sales exceeded $100,000 for the first quarter ending 8/31/2009. b) Sales have increased substantially in the past 7 days since the COPD Digest ad was published on 9- 14-2009. The COPD Digest is published for people suffering from Chronic Obstructive Pulmonary Disease. Mr. Sand explained how the nasal cannula works and how its introduction into the marketplace is boosting sales. The company has committed to ads with COPD Digest for all issues in 2010. Leadership Officers: Scott R. Sand CEO Thomas J. Neavitt CFO Christopher Wirth COO Board of Directors: Scott R. Sand Chairman John Finazzo, MD Director Stephen O’Hara, MD Director Charles Vorwaller Director Curt Miedema Director Christopher Wirth Director Yong Sin Khoo Director General Counsel: Richard Weed Weed & Co., LLP Legal Counsel: Pete Wilke Peter J. Wilke LLP Patent Attorney: Donn Harms American Trademark and Law Center Inc. Auditors: Gregory Anton Wahl, CPA Anton & Chia, LLP Accounting: Jon R. Marple, CPA White Rhino Consulting Inc. Ronald Mitchel, CPA Financial SEC Consultants: Keith Nuygen CDM Capital, LLC Investment Banking Firm: David Yang Pacific Pearl Group, LLP Engineering Consultants: Richard Campbell RC Product Development & Engineering, Inc. Robert Sand GV Engineering and Design Sales & Marketing: Jeff Morgan Director of Sales & Marketing Advertising Agencies: Mitch Rutner COPD Digest George Bogle ENet Technologies Rita Garson Medco Forum Publication Rick Priolo Today’s Senior Magazine |
| News |
del.icio.us 
Digg 
reddit 
Facebook 
StumbleUpon
1 comment:
Amazing post! I initially found your blog a week or so ago, and I want to subscribe to your RSS feed.
Sign supplies
Post a Comment